A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 611 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Olaparib June 27, 2022 Colonoscopy after Positive FIT Test Cuts Risk of Colorectal Cancer Death May 5, 2022 Coming Soon: Medicare Drug Price Negotiations September 1, 2023 Gene Tied to Alzheimer’s May Be Associated with Cancer-Related Cognitive Problems November 9, 2018 Load more HOT NEWS One in Five of Older Patients with EBC Treated in a... FDA Proposes Changes to Mammography Standards to Inform Women About Breast... EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where...
